




Cryomelt MN[®]



The active longevity
with Cryomelt MN



The problem of universal scale

According to WHO, between 2000 and 2050, the proportion of the world's population over the age of 60 will double from about 11% to 22%. The absolute number of people aged 60 and older will increase from 605 million to 2 billion people. Most of them will live to 80 and 90 years old, the number of older people who can not take care of themselves, in developed countries will increase by 4 times by 2050. Preventing premature aging and achieving active longevity is necessary for the state to reduce the burden on the budget and social services. It is also necessary for society to improve the living comfort of the elderly and reduce social tension.



Solution already found

We, the ALFATRADE company, have created a unique medicinal preparation CRYOMELT MN, which we propose to use to prevent the premature aging and to achieve the active longevity.

Studies have shown that CRYOMELT MN is a drug with anti-aging activity as a result of stimulation of recognition of genetically altered cells, including those infected by virus or tumor cells, followed by the destruction of these cells. This mechanism is unique and different from the well known, including the mechanism of interferon effects.



Solution already found

In addition, the CRYOMELT MN stimulates the expression of the receptor and the production of neurotrophic factors BDNF and NGF, which contributes to the prevention and treatment of most neurological diseases and the effects of neurotrauma, and, with respect to the anti-aging program, the prevention and treatment of senile dementia.

CRYOMELT MN is a highly effective adaptogenic agent in conditions of unfavorable ecology, chronic intoxication, electromagnetic smog, population and psychological stress.

CRYOMELT MN combines proven high efficiency with an excellent safety profile, has unique properties.



The commercialization of Cryomelt MN

The technology of production is patented.

We plan to create a partnership for the production and sale of the drug to consumers. Within the framework of such a partnership, we can sell intellectual property and technology licenses.

The main market of CRYOMELT MN is the prevention of premature aging and the achievement of active longevity.

Secondary - sports medicine and, given the antimutagenic properties of the drug, the elimination of the effects of environmental pollution.

Potential consumers are residents of developed countries with an average and above average income level.



The Intellectual property

- Registration certificate of medicinal product №LS-000135
- Trademark certificate No. 431724
- Patent No. 2506813
- Patent No.2407403
- International application PCT / RU2017 / 000544.



About ALFATRADER company

Company ALFATRADER began its activities as a developer of new drugs in 2008.

Since that time, we obtained an indefinite registration certificate of a medicinal product for the drug Cryomelt MN, which was created by the employees of our company, we conducted research on the specific properties of Cryomelt MN in cooperation with independent highly qualified laboratories, we developed a technology for the production of two more new drugs, the first for the treatment of diseases of the joints and fractures, and the second - for the treatment of dysfunctions of the nervous system, including those caused by age-related changes.



About ALFATRADER company

We have not started the registration procedure for these two drugs. We also developed a technology to improve the effectiveness of water-based injectable drugs.

ALFATRADER did not use bank loans or money from investors to finance its activities. ALFATRADER has no financial and no other obligations.

I believe that ALPHATRADER has fully completed its task.



About ALFATRADER company

Today ALPHATRADER does not conduct any economic activity.

I, as an individual, am the owner of patents protecting the production technology of the drug Cryomelt MN.

As the sole owner, I am ready to transfer the technology and rights that I possess to the company that will be engaged in the further commercialization of our projects.



The team of the Cryomelt MN project

Afanasev Serge.

ALFATRADE CEO. Project Manager.

Project management, interaction with organizations and individuals involved in the project.

Higher education. Peoples' Friendship University, Moscow.

Author and copyright holder of the intellectual property of the project:

Patent No. 2506813, Patent No. 2407403, International application PCT / RU2017 / 000544.



The team of the Cryomelt MN project

Volchek Igor.

Project Scientific Leader.

Professor, Doctor of Medicine.

Specialties: Therapy, Immunology, Allergology, sports and rehabilitation medicine. Military medicine.

Participation in the development of drugs Cortexin, Timalin, VG-1000, preparations based on recombinant erythropoietin and ER inhibitors - suppressors.

Published more than 100 academic works, 1 monograph.

The works were awarded prizes of international congresses.

Author of 17 inventions and 3 patents.



The team of the Cryomelt MN project

Fofanov Leonid.

Technical project manager.

Technical support of production and laboratory research.

Higher education. Civil Aviation Institute, Riga. Engineer - mechanic, engineer-economist, production management.

Co-author of the intellectual property of the project:

Patent No. 2506813, Patent No. 2407403, International Application PCT / RU2017 / 000544.



Contacts

ALFATRADE LTD.

Russia, Moscow, 127051 Bolshoi Karetny 22-2.

- e-mail : afflow2009@gmail.com.
- Tel: +79160419649.

CEO AFANASEV SERGE.